Research programme: metabolic disease therapeutics - Magnus
Alternative Names: Obesity therapeutics - Magnus; Type 2 diabetes mellitus therapeutics - Magnus MetabolicLatest Information Update: 28 Feb 2019
At a glance
- Originator Magnus Life Science; University College London
- Developer Magnus Life Science
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Metabolic-disorders in United Kingdom
- 28 Feb 2019 No recent reports of development identified for research development in Obesity in United Kingdom
- 28 Feb 2019 No recent reports of development identified for research development in Type-2-diabetes-mellitus in United Kingdom